205 Users Online
Antiplatelet therapy Market Segmented By Angioplasty procedures, Coronary artery bypass procedures, Arrhythmias especially atrial fibrillations prevention, Atherosclerosis prevention and Prevention of Myocardial infarction application having Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies distribution channel
Antiplatelet Therapy deals with prevention or obstruction of clump formation by platelets. Atherosclerosis is a condition in which the platelets get narrow and cause direct harm to blood flow. Antiplatelet therapy breaks those blood clots that cause harm to the blood flow.
Antiplatelet therapy is required in procedures of artificial heart valves and stents placements, coronary artery bypass procedure and angioplasty. These factors contribute to heart conditions. Antiplatelet therapy market is expanding due to its increasing usage in artificial heart valve placements, coronary artery bypass surgeries, angioplasty etc.
The death rate in the United States due to heart conditions is 630,000 each year. They contribute $200 billion to their health care expenditures caused specifically due to heart diseases. The estimate increase in mortality rate due to cardiac failures will be 22 million by 2030. Antiplatelet therapy Market is directly proportional to cardiac surgeries. The Antiplatelet therapy market is anticipated to increase due to increasing cardiac disorders.
The Antiplatelet therapy market is gaining demand due to increased mortality rate caused specifically by cardiac failures .Lifestyle changes is a leading cause of high blood pressure, increased cholesterol levels, physical inactivity, increase in blood sugar levels these are the factors which trigger the increase in heart-related disorders and eventually trigger the need for surgeries such as coronary bypass surgeries and angioplasty.
Smoking is also one of the factors responsible for cardiovascular diseases. There is a visible increase in the number of cardiac surgeries which is developing a scope for antiplatelet therapy market. Nations contributing larger portions to health care expenditure are also the once at high risks of heart diseases and cardiovascular diseases.
Antiplatelet therapy market is expected to be dominant in these regions such as North America. These regions indicates a positive development of antiplatelet therapy market. Antiplatelet therapy is a new addition to approaches towards cardiovascular diseases. Hematological researches are involved in antiplatelet therapy analysis for an alternative approach towards dealing with cardiac failures, myocardial infarctions, atherosclerosis, heart strokes and so on.
|By drug class||
|By distribution channel||
The dominant region in antiplatelet therapy market is expected to be the United States as there is a significant increase in the number of heart prone diseases. Europe contributes a major portion of heart prone diseases to the globe and is anticipated to be a significant player in antiplatelet therapy market. Asian countries such as China and India are majorly affected by cardiac failures and can be expected to have a growing market for antiplatelet therapy.
The key participants in antiplatelet therapy market are Espero Biopharma Inc., Teva Pharmaceuticals, Astra Zeneca Pharmaceuticals LP, Eli Lily and company, Daiichi Sankyo Europe GmbH, Pfizer Inc., CNW Group Ltd., SANIS, The Jean Coutu Group (PJC).Inc. , BRP Pharmaceuticals and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.